本帖最后由 老马 于 2012-1-13 21:20 编辑
' k5 ^$ G4 ?' Z7 J5 q" C. R+ U$ C- M: C+ v: T$ I& G: V+ M% ~
爱必妥和阿瓦斯丁的比较 t% G' h; E+ O& l
' k2 p! t. Z, ~% Q) K4 u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! d% q4 Z* u: p% u2 U; u. c
`# a# F- k9 \+ @
; ~+ z0 {( Y0 A1 H2 T) r) O
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ \ X1 H8 I, w/ Y==================================================
7 p! B+ S2 v- o0 G9 E% vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 p- t# i& p# E$ H, l; D
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. ?- O9 x, l4 i" Q7 a4 x: |" a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 k( {# N$ L8 \' F! V1 i S7 A
|